INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 130 filers reported holding INTRA CELLULAR THERAPIES INC in Q3 2015. The put-call ratio across all filers is 1.03 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $1,886,239 | +0.6% | 29,789 | -9.3% | 0.35% | -23.8% |
| Q2 2022 | $1,875,000 | -24.0% | 32,849 | -18.5% | 0.46% | -0.4% |
| Q1 2022 | $2,468,000 | +11.2% | 40,330 | -4.9% | 0.46% | +26.4% |
| Q4 2021 | $2,219,000 | +12.8% | 42,404 | -12.1% | 0.36% | +19.7% |
| Q2 2021 | $1,968,000 | +98.8% | 48,220 | +24.9% | 0.30% | +29.4% |
| Q3 2020 | $990,000 | +23.0% | 38,600 | +86.1% | 0.24% | +94.2% |
| Q2 2016 | $805,000 | -5.4% | 20,737 | -32.2% | 0.12% | -9.0% |
| Q1 2016 | $851,000 | -85.1% | 30,598 | -71.2% | 0.13% | -82.2% |
| Q4 2015 | $5,715,000 | +50.0% | 106,243 | +11.6% | 0.75% | +23.9% |
| Q3 2015 | $3,811,000 | -21.7% | 95,168 | -37.5% | 0.60% | +5.8% |
| Q2 2015 | $4,869,000 | +341.8% | 152,389 | +230.3% | 0.57% | +348.8% |
| Q1 2015 | $1,102,000 | – | 46,132 | – | 0.13% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ally Bridge Group (NY) LLC | 175,000 | $9,115,750 | 10.70% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 317,856 | $16,547,583 | 5.57% |
| Deep Track Capital, LP | 2,600,000 | $135,434,000 | 5.23% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,369,849 | $71,355,434 | 3.86% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 208,730 | $10,872,746 | 3.30% |
| DCF Advisers, LLC | 107,157 | $5,581,808 | 3.04% |
| Bellevue Group AG | 3,170,250 | $165,138,323 | 2.66% |
| Vahanian & Associates Financial Planning Inc. | 15,217 | $792,654 | 2.55% |
| Iron Triangle Partners LP | 330,549 | $17,218,297 | 2.52% |
| TANG CAPITAL MANAGEMENT LLC | 300,000 | $15,627,000 | 2.20% |